![](/images/graphics-bg.png)
Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients
المؤلفون المشاركون
Usera, Brittni M.
Creveling, Polly
Tward, Jonathan D.
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-01-20
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Purpose.
To investigate how pretreatment testosterone levels correlate with progression-free survival, metastasis-free survival, and overall survival in a propensity-adjusted localized prostate cancer population.
Methods.
Men diagnosed with clinical NCCN-risk stratified very-low, low, intermediate, high, and/or very-high risk prostate cancer who had a baseline total serum testosterone level≥100 ng/dl measured within the 100 days preceding the first definitive therapy were identified from our prospectively gathered institutional database.
Cohorts below (100–239 ng/dl), within (240–593 ng/dl), or above (594 + ng/dl) one standard deviation from the mean testosterone level (416 ng/dl) were used for comparison.
Progression-free, metastasis-free, and overall survival were evaluated.
A separate cohort of men not receiving ADT was used to evaluate testosterone recovery after various treatment modalities (surgery, external beam radiation, brachytherapy, or combined EBRT + Brachy).
Results.
There was no statistically significant difference between the low, average, and high testosterone cohorts for PFS, MFS, or OS.
In men not using ADT, there were no statistically significant changes in testosterone levels 1 year after therapy, regardless of therapy type.
Conclusion.
In men with serum testosterone levels >=100 ng/dl at diagnosis, baseline testosterone does not impact PFS, MFS, or OS.
Recovery of testosterone back to baseline is expected for men undergoing either surgery, external beam or brachytherapy, or combined modality radiation when not using ADT.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Usera, Brittni M.& Creveling, Polly& Tward, Jonathan D.. 2020. Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. Prostate Cancer،Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1206365
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Usera, Brittni M.…[et al.]. Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. Prostate Cancer No. 2020 (2020), pp.1-9.
https://search.emarefa.net/detail/BIM-1206365
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Usera, Brittni M.& Creveling, Polly& Tward, Jonathan D.. Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. Prostate Cancer. 2020. Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1206365
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1206365
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)